

3.721% p.a. ZKB Reverse Convertible Defensive on worst of Basilea Pharmaceutica AG/BKW AG/Julius Baer Gruppe AG

12/07/2024 - 14/04/2025 | Swiss Security Code 135 803 747

Summary

This Summary is to be understood as an introduction to the present Final Terms. Any investment decision in relation to the products must be based on the information contained in the Base Prospectus and in these Final Terms in their entirety and not on the Summary. In particular, each investor should consider the risk factors contained in these Final Terms and in the Base Prospectus.

The Issuer can only be held liable for the content of this Summary if the Summary is misleading, incorrect or contradictory when read together with the other parts of the Final Terms and the Base Prospectus.

Information on the securities	
Type of product:	ZKB Reverse Convertible on worst of
SSPA category:	Reverse Convertible (1220, acc. Swiss Structured Products Association)
ISIN:	CH1358037476
Issuer:	Zürcher Kantonalbank Finance (Guernsey) Limited, Guernsey
Underlyings:	Basilea Pharmaceutica AG/BKW AG/Julius Baer Gruppe AG
Initial Fixing Date:	05/07/2024
Payment Date:	12/07/2024
Final Fixing Date:	07/04/2025
Redemption Date:	14/04/2025
Cap Level:	73.00% of the Initial Fixing Value
Mode of settlement:	Cash or physical settlement
Coupon:	3.721% p.a. of Denomination
Information on the offer and admission to trading	
Place of the offer:	Switzerland
Issue amount/ Denomination/Trading units:	CHF 50,000, without the right to increase/CHF 10,000.00 Denomination per product/CHF 10,000 or multiples thereof
Issue price:	100.00% of Denomination (CHF 10,000.00)
Information on listing:	The product shall not be listed on an exchange.

Final Terms

**Derivative
Category/Designation
Regulatory Notification**

1. Product specific conditions and product description

Yield Enhancement / Reverse Convertible (1220, acc. Swiss Structured Products Association)

This product does not constitute a collective investment scheme within the meaning of the Swiss Federal Act on Collective Investment Schemes (CISA) and it is not subject to authorisation or supervision by FINMA. The issuer risk is borne by investors.

Issuer

Zürcher Kantonalbank Finance (Guernsey) Limited, Saint Peter Port, Guernsey
Zürcher Kantonalbank Finance (Guernsey) Limited is a wholly owned and fully consolidated subsidiary of Zürcher Kantonalbank. It is not subject to any direct prudential supervision neither in Guernsey nor in Switzerland and does not have a rating.

Keep-Well Agreement

Zürcher Kantonalbank Finance (Guernsey) Limited is a fully owned subsidiary of Zürcher Kantonalbank. Zürcher Kantonalbank obtains the following three ratings: Standard & Poor's: AAA, Moody's: Aaa, Fitch: AAA. Zürcher Kantonalbank is committed to Zürcher Kantonalbank Finance (Guernsey) Limited with sufficient financial means, allowing to satisfy any claims of its creditors in due time. The full text of the Keep-Well Agreement, which is subject to Swiss law, can be found in the publicly available Base Prospectus.

**Lead Manager, Paying Agent,
Exercise Agent and Calculation
Agent**

Zürcher Kantonalbank, Zurich

Swiss Security Code/ISIN	135 803 747/CH1358037476
Issue amount/ Denomination/Trading units	CHF 50,000, without the right to increase/CHF 10,000.00 Denomination per product/CHF 10,000 or multiples thereof
Issue price	100.00% of Denomination (CHF 10,000.00)
Currency	CHF
Currency Hedge	No
Mode of settlement	Cash or physical settlement

Underlying(s)

Underlying	Type of Underlying Domicile	ISIN Bloomberg	Reference exchange/ Price source
Basilea Pharmaceutica AG	registered share Switzerland	CH0011432447 BSLN SE Equity	SIX Swiss Exchange
BKW AG	registered share Switzerland	CH0130293662 BKW SE Equity	SIX Swiss Exchange
Julius Baer Gruppe AG	registered share Switzerland	CH0102484968 BAER SE Equity	SIX Swiss Exchange

Information on Levels

Underlying	Initial Fixing Value	Cap Level	Ratio
Basilea Pharmaceutica AG	CHF 39.15	CHF 28.5795 (73.00% of the Initial Fixing Value)	349.901153
BKW AG	CHF 149.60	CHF 109.208 (73.00% of the Initial Fixing Value)	91.568383
Julius Baer Gruppe AG	CHF 52.40	CHF 38.252 (73.00% of the Initial Fixing Value)	261.424239

* Local taxes, transactions fees and foreign commissions are, if applicable, included in the Initial Fixing Value of each component and are thus borne by the holders of the structured product. This applies particularly, though not exclusively, when exercising rights associated with the structured product and/or a Rebalancing.

Coupon 3.721% p.a. per Denomination CHF 10,000.00
Interest part: 0.7986%; Premium part: 2.0128%

Coupon Date(s)/ Coupon Payment(s)	Coupon Date _t *	Coupon Payment _t
t = 1	14/10/2024	0.9509%
t = 2	14/01/2025	0.9302%
t = 3	14/04/2025	0.9302%

* modified following business day convention

Coupon Calculation Method

30/360

Initial Fixing Date/ Initial Fixing Value

Basilea Pharmaceutica AG: Theoretically calculated price on 05/07/2024, 10:45:13 CET
BKW AG: Theoretically calculated price on 05/07/2024, 10:45:13 CET
Julius Baer Gruppe AG: Theoretically calculated price on 05/07/2024, 10:45:13 CET

Payment Date

12/07/2024

Last Trading Date

07/04/2025

Final Fixing Date/ Final Fixing Value

Basilea Pharmaceutica AG: Closing price on SIX Swiss Exchange on 07/04/2025
BKW AG: Closing price on SIX Swiss Exchange on 07/04/2025
Julius Baer Gruppe AG: Closing price on SIX Swiss Exchange on 07/04/2025

Redemption Date

14/04/2025

Redemption Method

If the Final Fixing Value of all Underlyings is at or above the Cap Level, the product will be redeemed in cash at Denomination.
If the Final Fixing Value of at least one Underlying is below its Cap Level, a physical delivery of the worst performing Underlying takes place (between Initial Fixing Date and Final Fixing Date). The number of Underlyings per Denomination is defined in Ratio (fractions will be paid in cash, no cumulation).
The Coupons are paid out on the respective Coupon Date not depending on the performance of the Underlyings.

Listing

The product shall not be listed on an exchange.

Secondary Market

Under normal market conditions, Zürcher Kantonalbank intends to provide bid prices for this

governed by their statutes.

Notifications

Any notice by the Issuer in connection with this product, in particular any notice in connection with modifications of the terms and conditions will be validly published on the website www.zkb.ch/finanzinformationen. The Swiss security code search button will lead you directly to the relevant product.

**Governing Law/
Jurisdiction**

Swiss Law/Zurich

**Profit and Loss Expectations at
Maturity**

2. Profit and Loss Expectations at Maturity

ZKB Reverse Convertible Defensive on worst of

Value	Percent	Redemption	Performance in %
Worst Underlying			
CHF 21.53	-45%	CHF 7815.39	-21.85%
CHF 27.41	-30%	CHF 9870.18	-1.30%
CHF 33.28	-15%	CHF 10281.14	2.81%
CHF 39.15	0%	CHF 10281.14	2.81%
CHF 45.02	15%	CHF 10281.14	2.81%
CHF 50.9	30%	CHF 10281.14	2.81%
CHF 56.77	45%	CHF 10281.14	2.81%

If the Final Fixing Value of all Underlyings is at or above the Cap Level, the performance of the product is always given by the Coupons paid out during the term. However, if the Final Fixing Value of at least one Underlying is below the Cap Level, the investor will receive a physical delivery of a number of Underlyings as defined in Ratio of the Underlying having the largest negative performance. Therefore, the investor may suffer a partial or total loss. The acquisition price of the delivered Underlyings is 73.00% of the Initial Fixing Value, which means that the performance of the product is less negative than the performance of the Underlying. This negative performance is reduced by the guaranteed Coupons paid out during the term. The table above is valid at maturity only and is by no means meant as a price indication for the present product throughout its lifetime. Additional risk factors may have a significant impact on the value of the product during the term. The price quoted on the secondary market can therefore deviate substantially from the above table. For this table it was assumed, that Basilea Pharmaceutica AG was the worst performing Underlying. This selection is just a representative example of the possible alternatives. Currency risks between the Underlyings and the Product are not considered in the table.

3. Material Risks for Investors

Issuer Risk

Obligations under these products constitute direct, unconditional and unsecured obligations of the Issuer and rank pari passu with other direct, unconditional and unsecured obligations of the Issuer. The value of the product not only depends on the performance of the Underlying and other developments in the financial markets, but also on the solvency of the Issuer, which may change during the term of this product.

Specific product risks

Structured products are complex financial instruments, which entail considerable risks and, accordingly, are only suitable for investors who have the requisite knowledge and experience and understand thoroughly the risks connected with an investment in these structured products and are capable of bearing the economic risks. The loss potential of an investment in ZKB Reverse Convertible Defensive on worst of in the case of a title delivery is limited to the difference between the purchase price of the product and the cumulative value of the number of Underlyings as defined in Ratio. The Coupon, which is paid out in any case, reduces the loss of the product compared to a direct investment in the worst performing Underlying. The product is denominated in CHF. If the investor's reference currency differs from the CHF, the investor bears the risk between the CHF and his reference currency.

4. Additional Terms

Modifications

If an extraordinary event as described in the Base Prospectus occurs in relation to an Underlying/Component of the Underlying or if any other extraordinary event occurs, which makes it impossible or particularly cumbersome for the Issuer, to fulfill its obligations under the products or to calculate the value of the products, the Issuer shall at its own discretion take all the necessary actions and, if necessary may modify the terms and conditions of these products at its own discretion in such way, that the economic value of the products after occurrence of the extraordinary event corresponds, to the extent possible, to the economic value of the products prior to the occurrence of the extraordinary event.

Change of Obligor

The Issuer is entitled at all times and without the consent of the investors to assign in whole (but not in part) the rights and claims under individual products or all of them to a Swiss or foreign subsidiary, branch or holding company of the Zürcher Kantonalbank (the "New Issuer") to the extent that (i) the New Issuer assumes all of the obligations arising out of the

assigned products which the previous Issuer owed in respect of these products, (ii) the Zürcher Kantonalbank enters into a Keep-Well Agreement with the New Issuer with terms equivalent to the one between the Zürcher Kantonalbank and Zürcher Kantonalbank Finance (Guernsey) Limited, (iii) the New Issuer has received from the supervisory authorities of the country in which it is domiciled all necessary approvals for the issue of products and the assumption of the obligations under the assigned products.

Market Disruptions

Compare specific provisions in the Base Prospectus.

Prudential Supervision

As a bank within the meaning of the Swiss Federal Act on Banks and Savings Banks (BankG; SR 952.0) and a securities firm within the meaning of the Swiss Federal Act on Financial Institutions (FinIAG; SR 954.1), Zürcher Kantonalbank is subject to the prudential supervision of FINMA, Laupenstrasse 27, CH-3003 Bern, <https://www.finma.ch>.

Recording of Telephone Conversations

Investors are reminded, that telephone conversations with trading or sales units of the Zürcher Kantonalbank are recorded. Investors, who have telephone conversations with these units consent tacitly to the recording.

Further indications

This document constitutes neither an offer nor a recommendation or invitation to purchase financial instruments and can't replace the individual investor's own judgement. The information contained in this document does not constitute investment advice but is intended solely as a product description. An investment decision should in any case be made on the basis of these Final Terms and the Base Prospectus. Particularly, before entering into a transaction, the investor should, if necessary with the assistance of an advisor, examine the conditions for investment in the product in consideration of his personal situation with regard to legal, regulatory, tax and other consequences. Only an investor who is aware of the risks of the transaction and has the financial capacity to bear any losses should enter into such transactions.

Material Changes

Since the end of the last financial year or the date of the interim financial statements, there have been no material changes in the assets, financial or revenue position of the Issuer and Zürcher Kantonalbank.

Responsibility for the Final Terms

Zürcher Kantonalbank, Zurich, and Zürcher Kantonalbank Finance (Guernsey) Limited, Guernsey, assume responsibility for the content of these Final Terms and hereby declare that, to their knowledge, the information contained in these Final Terms is correct and no material circumstances have been omitted.

Zurich, 05/07/2024